Sarepta Therapeutics Stock Analysis (NASDAQ:SRPT)

Add to My Stocks
$35.81 $1.79 (5.26%) SRPT stock closing price Apr 25, 2017 (Closing)
Watch Robo Advisor Video of SRPT Stock Analysis
Sarepta Therapeutics
Updated on : Apr 25, 2017
previous close
SRPT 35.8 (0%)
S&P 500 2388.6 (0%)
Closing Price On: Apr 25, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Biomed-Genetics
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q4
$million
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
-35.1%
5 Quarter Net Profit
Net Margins
2016-Q4
%
LTM Margin
Debt/Equity Ratio
Debt:
16.1M
Debt/Equity Ratio:
 0.05
Compared to the industry
Cash Flow
Operating cash flow:
-$81.2M
Net Income:
-$88.5M
PROS      CONS
Low Debt Burden
Long Term Growth
Net Margins
ROE
FCF Margin
Rating: ★★★★★★★★★★ (0/5)
Other Metrics
Return on Equity:
-99.5%
Free Cash Flow Margin:
-388.2%
Double Tap To Exit Full Screen
0:00
/

Sarepta Therapeutics Analysis Video

152 5 2

View Sarepta Therapeutics stock analysis video. This is our SRPT analyst opinion covering the buy and sell arguments for SRPT stock.

Sarepta Therapeutics Inc Stock Rating (1/5)

Our Sarepta Therapeutics stock opinion is based on fundamentals of the company. This Sarepta Therapeutics stock analysis is based on latest Q4 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy SRPT stock?

  • Sarepta Therapeutics has a lower debt burden than its peers in the Medical sector, with a debt/equity ratio of  0.05.

Should you sell SRPT stock?

  • Sales declined by -35.1% annually over the last 5 years.
  • Sarepta Therapeutics posted an average Net loss of -4931% in the last twelve months.
  • A negative ROE of -99.5% indicates that the company is not able to generate profits with the money shareholders have invested.
  • The company has a negative free cash flow margin of -388.2%.

Comments on this video and Sarepta Therapeutics stock